The HIV Coinfections and HIV Associated Cancers (HCAC) study section reviews applications pertaining to pathogen coinfections with HIV and opportunistic infections due to HIV-associated compromise of the immune system. HCAC also reviews applications with a focus on AIDS-defining cancers in the context of HIV infection and/or AIDS and non-AIDS-defining cancers in people living with chronic HIV infection and/or combination antiretroviral drug therapies (cART). Applications can address all aspects of molecular, animal model and clinical studies.
This study section operates on an expedited cycle as mandated by Congress and only applications in which there is a clear and compelling HIV/AIDS research component (HIV/AIDS-associated) are eligible for review in HCAC. Applications focused on opportunistic pathogens and cancers must make a clear connection between the goals of the study and HIV/AIDS. Those deemed insufficiently related to HIV/AIDS, including applications addressing basic immunology and/or co-morbidities of general relevance, are assigned to other non-expedited study sections and must be submitted in time to meet these regular application due dates.
The membership panel is a list of chartered members only.
- Molecular, cellular, and immunological studies of the pathogenesis of HIV/AIDS-associated opportunistic pathogens (including viral, fungal, parasitic and bacterial pathogens)
- Studies of HIV/AIDS-associated opportunistic pathogens in immunocompromised situations
- Studies of AIDS-defining cancers (e.g., Kaposi, lymphoma and cervical) and their causative viruses (e.g., KSHV, EBV and HPV.
- Studies of non-AIDS-defining cancers (e.g., liver, lung, oral) in people living with chronic HIV infection and/or cART
- Immune regulated therapeutic strategies for HIV/AIDS-associated opportunistic pathogens and cancers
- Preclinical and clinical ramifications and development of therapeutic approaches for opportunistic infections and HIV-associated and non-associated malignancies
- Mechanisms predisposing the elderly and infants to HIV coinfections and HIV associated malignancies
Shared Interests and Overlaps (HIV/AIDS related):
There are shared interests with HIV Comorbidities and Clinical Studies Study Section (HCCS). Clinical studies focused on the effects of chronic HIV infection and/or antiretroviral drug therapy on end-organ diseases may be reviewed in HCCS, while those focused on clinical studies related to HIV/AIDS-associated opportunistic infections and/or cancer, and certain non-clinical studies of HIV-associated end-organ disease, may be reviewed here.
There are shared interests with HIV Molecular Virology, Cell Biology, and Drug Development (HVCD). Pre-clinical development studies of antiretroviral drugs, drug delivery and drug resistance may be reviewed in HVCD, while those focused on pre-clinical and clinical development of therapeutics for opportunistic infectious diseases and AIDS-associated malignancies, in the context of HIV infection, may be reviewed here.
There are shared interests with HIV Immunopathogenesis and Vaccine Development (HIVD). Studies that address immune mechanisms and vaccines for HIV-associated opportunistic pathogens may be reviewed in HIVD, while those focused on immunopathogenesis associated with opportunistic infections, in the context of HIV infection, may be reviewed here.
There are shared interests with Population and Public Health Approaches to HIV/AIDS (PPAH). Studies of HIV coinfections and HIV associated cancers in human populations employing behavioral measures and/or behavioral outcomes may be reviewed in PPAH, while those focused on HIV coinfections and HIV associated cancers in human populations employing biological assays and/or focusing on biological outcomes may be reviewed here.
Shared Interests and Overlaps (Non-AIDS related):
Infectious diseases, microbiology, and immunology applications not associated with HIV/AIDS are reviewed in the Infectious Diseases and Immunology A (IDIA) IRG, the Infectious Diseases and Immunology B (IDIB) IRG, or the Applied Immunology and Disease Control (AIDC) IRG as appropriate.
The Oncology 1 – Basic Translational (OBT) IRG reviews applications involving basic and translational investigations that encompass cancer initiation, promotion, progression, and metastasis.
The Oncology 2 – Translational Clinical (OTC) IRG reviews applications involving translational and clinical investigations that encompass cancer prevention, diagnosis and treatment./p>